CA2085603A1 - Derives d'hormones secretees par le lobe posterieur de la glande pituitaire - Google Patents

Derives d'hormones secretees par le lobe posterieur de la glande pituitaire

Info

Publication number: CA2085603A1
Authority: CA; Canada
Prior art keywords: peptide; thr; tyr; mpa; pro
Prior art date: 1990-07-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002085603A

Other languages

English (en)

Inventor

Jerzy Trojnar

Michal Lebl

Per Melin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ferring AB

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-07-09

Filing date

1991-07-04

Publication date

1992-01-10

1991-07-04 Application filed by Individual filed Critical Individual

1992-01-10 Publication of CA2085603A1 publication Critical patent/CA2085603A1/fr

Status Abandoned legal-status Critical Current

Links

229940088597 hormone Drugs 0.000 title abstract description 8
239000005556 hormone Substances 0.000 title abstract description 8
210000001883 posterior pituitary gland Anatomy 0.000 title abstract description 7
OXDZADMCOWPSOC-UHFFFAOYSA-N Argiprestocin Chemical class N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 OXDZADMCOWPSOC-UHFFFAOYSA-N 0.000 claims abstract description 22
210000004291 uterus Anatomy 0.000 claims abstract description 18
239000000203 mixture Substances 0.000 claims abstract description 10
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical group OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims abstract description 8
238000001990 intravenous administration Methods 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
RMYPEYHEPIZYDJ-SNVBAGLBSA-N (2r)-2-azaniumyl-3-(4-ethoxyphenyl)propanoate Chemical group CCOC1=CC=C(C[C@@H](N)C(O)=O)C=C1 RMYPEYHEPIZYDJ-SNVBAGLBSA-N 0.000 claims abstract description 5
125000002849 D-tyrosine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims abstract description 4
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims abstract description 3
150000008575 L-amino acids Chemical group 0.000 claims abstract description 3
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract description 3
230000001225 therapeutic effect Effects 0.000 claims abstract description 3
230000004118 muscle contraction Effects 0.000 claims abstract 3
238000000034 method Methods 0.000 claims description 28
-1 3-mercaptopropionyl residue Chemical group 0.000 claims description 9
239000000654 additive Substances 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
YZJSUQQZGCHHNQ-UHFFFAOYSA-N Homoglutamine Chemical compound OC(=O)C(N)CCCC(N)=O YZJSUQQZGCHHNQ-UHFFFAOYSA-N 0.000 claims description 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
125000001711 D-phenylalanine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical group CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 description 86
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
230000000694 effects Effects 0.000 description 30
102000004196 processed proteins & peptides Human genes 0.000 description 28
239000000556 agonist Substances 0.000 description 18
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
238000003786 synthesis reaction Methods 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 15
239000011347 resin Substances 0.000 description 14
229920005989 resin Polymers 0.000 description 14
102400000050 Oxytocin Human genes 0.000 description 13
101800000989 Oxytocin Proteins 0.000 description 13
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 13
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 13
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 13
229960001723 oxytocin Drugs 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 12
OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 11
101710176384 Peptide 1 Proteins 0.000 description 11
241000700159 Rattus Species 0.000 description 11
238000004128 high performance liquid chromatography Methods 0.000 description 11
238000012360 testing method Methods 0.000 description 11
235000001014 amino acid Nutrition 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
230000008602 contraction Effects 0.000 description 10
230000003042 antagnostic effect Effects 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
239000005557 antagonist Substances 0.000 description 8
239000000047 product Substances 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
238000010168 coupling process Methods 0.000 description 7
238000005859 coupling reaction Methods 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 6
230000008878 coupling Effects 0.000 description 6
239000013558 reference substance Substances 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
101800003024 Vasotocin Proteins 0.000 description 5
238000013019 agitation Methods 0.000 description 5
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
239000012071 phase Substances 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
150000003862 amino acid derivatives Chemical class 0.000 description 4
230000037396 body weight Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
125000002698 D-tryptophano group Chemical group C(=O)(O)[C@@H](CC1=CNC2=CC=CC=C12)N* 0.000 description 3
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000001270 agonistic effect Effects 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
239000007788 liquid Substances 0.000 description 3
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 3
210000000754 myometrium Anatomy 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
WMSUFWLPZLCIHP-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 9h-fluoren-9-ylmethyl carbonate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)ON1C(=O)CCC1=O WMSUFWLPZLCIHP-UHFFFAOYSA-N 0.000 description 2
CQBLOHXKGUNWRV-SFHVURJKSA-N 1-o-(9h-fluoren-9-ylmethyl) 2-o-(2,3,4,5,6-pentafluorophenyl) (2s)-pyrrolidine-1,2-dicarboxylate Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1OC(=O)[C@H]1N(C(=O)OCC2C3=CC=CC=C3C3=CC=CC=C32)CCC1 CQBLOHXKGUNWRV-SFHVURJKSA-N 0.000 description 2
XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
244000025254 Cannabis sativa Species 0.000 description 2
OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
229940122828 Oxytocin receptor antagonist Drugs 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
208000036029 Uterine contractions during pregnancy Diseases 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000001158 estrous effect Effects 0.000 description 2
ZTVZLYBCZNMWCF-UHFFFAOYSA-N homocystine Chemical compound [O-]C(=O)C([NH3+])CCSSCCC([NH3+])C([O-])=O ZTVZLYBCZNMWCF-UHFFFAOYSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
WXEHBUMAEPOYKP-UHFFFAOYSA-N methylsulfanylethane Chemical compound CCSC WXEHBUMAEPOYKP-UHFFFAOYSA-N 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
229960003104 ornithine Drugs 0.000 description 2
IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
FESVUEALWMQZEP-INIZCTEOSA-N (2,3,4,5,6-pentafluorophenyl) (2s)-4-amino-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxobutanoate Chemical compound O=C([C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)N)OC1=C(F)C(F)=C(F)C(F)=C1F FESVUEALWMQZEP-INIZCTEOSA-N 0.000 description 1
FYZSBHSHLNJGPS-RZFZLAGVSA-N (2,3,4,5,6-pentafluorophenyl) (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoate Chemical compound O=C([C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)[C@@H](C)CC)OC1=C(F)C(F)=C(F)C(F)=C1F FYZSBHSHLNJGPS-RZFZLAGVSA-N 0.000 description 1
VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
241001514645 Agonis Species 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101800005164 Peptide V Proteins 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
206010036600 Premature labour Diseases 0.000 description 1
229940116211 Vasopressin antagonist Drugs 0.000 description 1
SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000002686 anti-diuretic effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical class C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
230000006651 lactation Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000002632 myometrial effect Effects 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
IDELNEDBPWKHGK-UHFFFAOYSA-N thiobutabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=S)NC1=O IDELNEDBPWKHGK-UHFFFAOYSA-N 0.000 description 1
230000003191 uterotonic effect Effects 0.000 description 1
238000011121 vaginal smear Methods 0.000 description 1
239000003038 vasopressin antagonist Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Steroid Compounds (AREA)

CA002085603A 1990-07-09 1991-07-04 Derives d'hormones secretees par le lobe posterieur de la glande pituitaire Abandoned CA2085603A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9002384-7		1990-07-09
SE9002384A SE9002384D0 (sv)	1990-07-09	1990-07-09	Derivat av baklobshormoner

Publications (1)

Publication Number	Publication Date
CA2085603A1 true CA2085603A1 (fr)	1992-01-10

Family

ID=20379963

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002085603A Abandoned CA2085603A1 (fr)	1990-07-09	1991-07-04	Derives d'hormones secretees par le lobe posterieur de la glande pituitaire

Country Status (11)

Country	Link
EP (1)	EP0538367A1 (fr)
JP (1)	JPH05508849A (fr)
AU (1)	AU8225191A (fr)
CA (1)	CA2085603A1 (fr)
FI (1)	FI930013A7 (fr)
IE (1)	IE912378A1 (fr)
IL (1)	IL98737A0 (fr)
MC (1)	MC2291A1 (fr)
PL (1)	PL297600A1 (fr)
SE (1)	SE9002384D0 (fr)
WO (1)	WO1992000996A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2149880T3 (es) *	1993-06-29	2000-11-16	Ferring Bv	Sintesis de peptidos ciclicos.
SE501678C2 (sv) *	1993-07-13	1995-04-10	Ferring Bv	Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE9604341D0 (sv) *	1996-11-26	1996-11-26	Ferring Bv	Hepta-peptide oxytocin analogue
EP1480998B1 (fr)	2002-02-27	2006-11-22	Ferring BV	Intermediaires et procedes destines a fabriquer des analogues d'oxytocine heptapeptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3363830D1 (en) *	1982-12-21	1986-07-03	Ferring Ab	Vasotocin derivatives
US4483794A (en) *	1983-05-10	1984-11-20	Ceskoslovenska Akademie Ved	Analogs of neurohypophysial hormones
US4599324A (en) *	1984-11-21	1986-07-08	Smithkline Beckman Corporation	V1-vasopressin antagonists
US4604378A (en) *	1984-11-21	1986-08-05	Smithkline Beckman Corporation	Basic V1 -vasopressin antagonists
EP0247033A1 (fr) *	1985-10-25	1987-12-02	Gibson-Stephens Neuropharmaceuticals, Inc.	Antagonistes de l'oxytocine a conformation limitee presentant des activites biologiques prolongees

1990
- 1990-07-09 SE SE9002384A patent/SE9002384D0/xx unknown
1991
- 1991-07-04 IL IL98737A patent/IL98737A0/xx unknown
- 1991-07-04 PL PL29760091A patent/PL297600A1/xx unknown
- 1991-07-04 JP JP91512399A patent/JPH05508849A/ja active Pending
- 1991-07-04 EP EP91913318A patent/EP0538367A1/fr not_active Withdrawn
- 1991-07-04 WO PCT/SE1991/000477 patent/WO1992000996A1/fr not_active Ceased
- 1991-07-04 CA CA002085603A patent/CA2085603A1/fr not_active Abandoned
- 1991-07-04 MC MC91@@D patent/MC2291A1/fr unknown
- 1991-07-04 AU AU82251/91A patent/AU8225191A/en not_active Abandoned
- 1991-07-08 IE IE237891A patent/IE912378A1/en unknown
1993
- 1993-01-04 FI FI930013A patent/FI930013A7/fi not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL297600A1 (fr)	1992-07-13
FI930013A0 (fi)	1993-01-04
JPH05508849A (ja)	1993-12-09
AU8225191A (en)	1992-02-04
FI930013A7 (fi)	1993-01-04
WO1992000996A1 (fr)	1992-01-23
IL98737A0 (en)	1992-07-15
IE912378A1 (en)	1992-01-15
EP0538367A1 (fr)	1993-04-28
MC2291A1 (fr)	1993-07-14
SE9002384D0 (sv)	1990-07-09

Publication	Publication Date	Title
JP3405460B2 (ja)	2003-05-12	ヘプタペプチドオキシトシン類似体
BE1004357A4 (fr)	1992-11-10	Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments.
CA2718148C (fr)	2017-11-07	Analogues d'ocytocine
FI104252B (fi)	1999-12-15	Menetelmä terapeuttisesti käyttökelpoisten peptidien kemialliseksi syntetisoimiseksi kiinteässä faasissa
CA1216843A (fr)	1987-01-20	Derives de vasotocine
JP2024520861A (ja)	2024-05-24	遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体
TW201114434A (en)	2011-05-01	Oxytocin receptor agonists
JPS63154699A (ja)	1988-06-27	バソプレシン拮抗剤
US4490364A (en)	1984-12-25	CCK Agonists II
US4604378A (en)	1986-08-05	Basic V1 -vasopressin antagonists
EP0269299A2 (fr)	1988-06-01	Peptides atriaux
KR100360975B1 (ko)	2003-01-24	위장운동자극활성을가지는폴리펩티드
US4684622A (en)	1987-08-04	Compositions and methods for producing vasodilation and antioxytocic activity
CA2085603A1 (fr)	1992-01-10	Derives d'hormones secretees par le lobe posterieur de la glande pituitaire
US4599324A (en)	1986-07-08	V1-vasopressin antagonists
EP1261626A1 (fr)	2002-12-04	Analogues de bombesine utilises dans le traitement du cancer
US4684621A (en)	1987-08-04	Methods of producing vasodilation or antioxytocic activity
US4826813A (en)	1989-05-02	4'-Methyl-β-mercapto-β,β-cyclopentamethylenepropionic acid vasopressin antagonists
US4658015A (en)	1987-04-14	Polypeptide intermediates
CA2163114A1 (fr)	1995-01-26	Peptides presentant une activite antagoniste pour l'oxytocine
CZ993A3 (en)	1993-07-14	derivatives of neurohypophysis lobe hormones
JPH0717999A (ja)	1995-01-20	ペプチド誘導体及びその用途

Legal Events

Date	Code	Title	Description
1997-07-04	FZDE	Discontinued